Helena Edlund

Helena Edlund

Auto-generated profile, based on publicly available information

Helena Edlund

Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, R&D AstraZeneca Gothenburg Sweden

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2014 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
HEHelena Edlund
Helena Edlund
JMJohanna Melin
Johanna Melin
ZPZinnia Patricia Parra-Guillen
Zinnia Patricia Parra-Guillen
CKCharlotte Kloft
Charlotte Kloft

13 October 2016 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
HEHelena Edlund
Helena Edlund
CSCasper Steenholdt
Casper Steenholdt
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
EGEva Goebgen
Eva Goebgen
JBJørn Brynskov
Jørn Brynskov
CKCharlotte Kloft
Charlotte Kloft

17 December 2018 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
HEHelena Edlund
Helena Edlund
SLSun Ku Lee
Sun Ku Lee
MAMarilee A. Andrew
Marilee A. Andrew
JSJ. Greg Slatter
J. Greg Slatter
SASergey Aksenov
Sergey Aksenov
NANidal Al-Huniti
Nidal Al-Huniti

17 October 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HEHelena Edlund
Helena Edlund
NBNúria Buil‐Bruna
Núria Buil‐Bruna
KVKarthick Vishwanathan
Karthick Vishwanathan
HWHelen Wei
Helen Wei
RRRakesh Raman
Rakesh Raman
SSShringi Sharma
Shringi Sharma
Aims: Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next‐generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP‐5862) vs. efficacy and safety responses in patients with B‐cell malignancies who received acalabrutinib as monotherapy or in combination with obinutuzumab.Methods: For exposure–efficacy analyses, patients with untreated chronic lymphocytic leukaemia were assessed for best overall response, progression‐free survival and tumour regression. For exposure–safety analyses, incidences of grade ≥2 adverse events (AEs), grade ≥3 AEs and grade ≥2 events of clinical interest were assessed in patients with B‐cell malignancies. Acalabrutinib and ACP‐5862 pharmacokinetic (PK) parameter estimates were obtained from population PK modelling. Exposure calculations were based on study dosing regimens. Total active moieties were calculated to account for contributions of ACP‐5862 to overall efficacy/safety.Results: A total of 573 patients were included (exposure–efficacy analyses, n = 274; exposure–safety analyses, n = 573). Most patients (93%) received acalabrutinib 100 mg twice daily. Median total active area under the concentration–time curve (AUC24h,ss) and total active maximal concentration at steady‐state (Cmax,ss) were similar for patients who received acalabrutinib as monotherapy or in combination with obinutuzumab, and for responders and nonresponders. No relationship was observed between AUC24h,ss/Cmax,ss and progression‐free survival or tumour regression. Acalabrutinib AUC24h,ss and Cmax,ss were generally comparable across groups regardless of AE incidence.Conclusion: No clinically meaningful correlations between acalabrutinib PK exposure and efficacy and safety outcomes were observed. These data support the fixed acalabrutinib dose of 100 mg twice daily in the treatment of patients with B‐cell malignancies.

21 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HEHelena Edlund
Helena Edlund
FBFrancesco Bellanti
Francesco Bellanti
HLHuan Liu
Huan Liu
KVKarthick Vishwanathan
Karthick Vishwanathan
HTHelen Tomkinson
Helen Tomkinson
NBNúria Buil‐Bruna
Núria Buil‐Bruna
This analysis aimed to describe the pharmacokinetics (PK) of acalabrutinib and its active metabolite, ACP‐5862. A total of 8935 acalabrutinib samples from 712 subjects and 2394 ACP‐5862 samples from 304 subjects from 12 clinical studies in patients with B‐cell malignancies and healthy subjects were analysed by nonlinear mixed‐effects modelling. Acalabrutinib PK was characterized by a 2‐compartment model with first‐order elimination. The large variability in absorption was adequately described by transit compartment chain and first‐order absorption, with between‐occasion variability on the mean transit time and relative bioavailability. The PK of ACP‐5862 was characterized by a 2‐compartment model with first‐order elimination, and the formation rate was defined as the acalabrutinib clearance multiplied by the fraction metabolized. Health status, Eastern Cooperative Oncology Group performance status, and coadministration of proton‐pump inhibitors were significant covariates. However, none of the investigated covariates led to clinically meaningful changes in exposure, supporting a flat dosing of acalabrutinib.

1 January 2006 in Gastroentérologie Clinique Et Biologique
Verified
Journal Article
Closed access
Jean-SéBastien AnnicotteJean-SéBastien Annicotte
Jean-SéBastien Annicotte
EFE. Fayard
E. Fayard
GSG.H. Swift
G.H. Swift
LSL. Selander
L. Selander
HEH. Edlund
H. Edlund
JAJohan Auwerx
Johan Auwerx